Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
2 mg | In stock | $ 53.00 | |
5 mg | In stock | $ 87.00 | |
10 mg | In stock | $ 147.00 | |
25 mg | In stock | $ 267.00 | |
50 mg | In stock | $ 441.00 | |
100 mg | In stock | $ 649.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 109.00 |
Description | Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections. |
In vitro |
METHODS: Primary rat cirrhotic hepatocytes were treated with Emricasan (50 µM) for 24 h, and mRNA expression levels were measured. RESULTS: Emricasan directly improved the expression of hepatocyte-specific markers. [1] METHODS: Human cervical cancer cells HeLa were pretreated with Emricasan (10 µM) for 1 h, then treated with vincristine (20 nM) for 44 h. Cell death was detected by Flow Cytometry. RESULTS: Emricasan eliminated 95% of vincristine-mediated cell death. [2] |
In vivo |
METHODS: To study the effects on chronic liver disease, Emricasan (10 mg/kg, 0.9% dimethylcarboxycellulose) was administered orally once daily for seven days to rats with advanced cirrhosis due to chronic CCl4 administration. RESULTS: Emricasan ameliorated hepatic sinusoidal microvascular dysfunction in cirrhotic patients, resulting in significant improvement in fibrosis, portal hypertension and liver function. [1] METHODS: To investigate the effects on cirrhosis, Emricasan (10 mg/kg) was administered intraperitoneally once daily for 10-20 days to C57BL/6 mice with secondary biliary cirrhosis induced by bile duct ligation (BDL). RESULTS: Emricasan treatment improved survival and portal hypertension (PHT) in a mouse model of long-term BDL. [3] |
Cell Research | Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference) |
Synonyms | PF 03491390, IDN-6556 |
Molecular Weight | 569.5 |
Formula | C26H27F4N3O7 |
CAS No. | 254750-02-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (163.3 mM)
Ethanol: 93 mg/mL (163.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Emricasan 254750-02-2 Apoptosis Microbiology/Virology Proteases/Proteasome Caspase Influenza Virus Inhibitor IDN 6556 PF-03491390 IDN6556 PF03491390 inhibit PF 03491390 IDN-6556 inhibitor